CVRX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CVRX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, CVRx's enterprise value is $107.25 Mil. CVRx's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $42.09 Mil. Therefore, CVRx's EV-to-Revenue for today is 2.55.
The historical rank and industry rank for CVRx's EV-to-Revenue or its related term are showing as below:
During the past 5 years, the highest EV-to-Revenue of CVRx was 19.44. The lowest was -2.44. And the median was 6.33.
The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.
EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.
As of today (2024-05-13), CVRx's stock price is $7.27. CVRx's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $2.01. Therefore, CVRx's PS Ratio for today is 3.61.
The historical data trend for CVRx's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CVRx Annual Data | |||||||||||
Trend | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | ||||||
EV-to-Revenue | - | - | 8.24 | 12.44 | 15.18 |
CVRx Quarterly Data | ||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
EV-to-Revenue | Get a 7-Day Free Trial | 3.95 | 7.94 | 7.06 | 15.18 | - |
For the Medical Devices subindustry, CVRx's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, CVRx's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where CVRx's EV-to-Revenue falls into.
EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.
CVRx's EV-to-Revenue for today is calculated as:
EV-to-Revenue | = | Enterprise Value (Today) | / | Revenue (TTM) |
= | 107.246 | / | 42.086 | |
= | 2.55 |
CVRx's current Enterprise Value is $107.25 Mil.
CVRx's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $42.09 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CVRx (NAS:CVRX) EV-to-Revenue Explanation
The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.
CVRx's PS Ratiofor today is calculated as:
PS Ratio | = | Share Price (Today) | / | Revenue per Share (TTM) |
= | 7.27 | / | 2.014 | |
= | 3.61 |
CVRx's share price for today is $7.27.
CVRx's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.01.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of CVRx's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Johnson & Johnson Innovation - Jjdc, Inc. | 10 percent owner | 410 GEORGE STREET, NEW BRUNSWICK NJ 08901 |
Paul Verrastro | officer: Chief Marketing Officer | 9201 W BROADWAY AVE, #650, MINNEAPOLIS MN 55445 |
Kevin Hykes | director | 2 GOODYEAR, SUITE B, IRVINE CA 92618 |
Kirk G. Nielsen | director | ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104 |
Mudit K. Jain | director | C/O TREO VENTURES, 140 WASHINGTON STREET, SUITE 200, RENO NV 89503 |
Craig E. Palmer | officer: SVP, U.S. Sales | 9201 WEST BROADWAY AVENUE, SUITE 650, MINNEAPOLIS MN 55445 |
Martha Shadan | director | 9201 W BROADWAY AVE, #650, MINNEAPOLIS MN 55445 |
New Enterprise Associates 10 L P | 10 percent owner | |
Nea Partners 10 L P | 10 percent owner | 1119 ST PAUL STREET, BALTIMORE MD 21202 |
Geoffrey B Pardo | director | 100 DOMAIN DRIVE, EXETER NH 03833 |
Jared Oasheim | officer: Chief Financial Officer | 9201 W BROADWAY AVE, #650, MINNEAPOLIS MN 55445 |
John Brintnall | officer: Chief Strategy Officer and Sec | 9201 W BROADWAY AVE, #650, MINNEAPOLIS MN 55445 |
Dean Bruhn-ding | officer: VP of Reg. Affairs and QA | 9201 W BROADWAY AVE, #650, MINNEAPOLIS MN 55445 |
Liz Galle | officer: VP of Global Clinical Research | 9201 W BROADWAY AVE, #650, MINNEAPOLIS MN 55445 |
Nadim Yared | director, officer: Chief Executive Officer | 9201 W BROADWAY AVE #650, MINNEAPOLIS MN 55445 |
From GuruFocus
By Tiesvg Tiesvg • 12-20-2022
By GuruFocus Research • 10-26-2023
By GlobeNewswire • 07-11-2023
By Marketwired • 11-03-2023
By Marketwired • 06-22-2023
By GuruFocusNews GuruFocusNews • 07-02-2022
By GuruFocusNews GuruFocusNews • 07-08-2022
By sperokesalga sperokesalga • 04-20-2023
By Marketwired • 10-12-2023
By sperokesalga sperokesalga • 03-01-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.